| HOME >> BIOLOGY >> TECHNOLOGY |
2008 2007 2008 2007
(unaudited) (unaudited)
Revenues:
Sponsored research and
development $32 $13 $48 $120
License fees and milestones 729 500 3,189 500
Grant Revenue - 27 9 72
Total revenues 761 540 3,246 692
Operating expenses:
Research and development 12,993 19,795 43,406 57,645
Sales, general and
administrative 3,472 9,571 16,423 26,695
Total operating expenses 16,465 29,366 59,829 84,340
Loss from operations (15,704) (28,826) (56,583) (83,648)
Other income and (expenses):
Interest income and expense,
net (93) 2,413 2,573 6,869
Other income and (expense),
net (1,914) (827) (5,749) (2,545)
Total other income (2,007) 1,586 (3,176) 4,324
Net loss $(17,711) $(27,240) $(59,759) $(79,324)
Net loss per common share:
Basic and diluted $(0.46) $(0.72) $(1.56) $(2.09)
Shares used in the calculation
of net loss per common share:
Basic and diluted 38,446 37,990 38,399 37,956
NEUROCRINE BIOSCIENCES, INC.
Condensed Consolidated Statements of Operations
(in thousands, except for per share data)
September December
30, 31,
'/>"/>
| SOURCE Neurocrine Biosciences, Inc. Copyright©2008 PR Newswire. All rights reserved |